Risk-based treatment approaches for neuroblastoma have been ongoing for decades.
However, the criteria used to define risk in various institutional and cooperative groups were …

Introduction: Children with neuroblastoma have widely divergent outcomes, ranging from
cure in> 90% of patients with low risk disease to< 50% for those with high risk disease …

PURPOSE Treatment planning for children with neuroblastoma requires accurate
assessment of prognosis. The most recent Children's Oncology Group (COG) risk …

Metastasis is the major cause of cancer-related deaths. Neuroblastoma (NB), a childhood
tumor has been molecularly defined at the primary cancer site, however, the bone marrow …

Estimated 5‐year survival rates for patients with non‐high‐risk and high‐risk neuroblastoma
are 90% and 50%, respectively. Recent clinical trials have shown excellent outcomes with …

Background: In the INRG dataset, the hypothesis that any segmental chromosomal alteration
might be of prognostic impact in neuroblastoma without MYCN amplification (MNA) was …

Neuroblastoma is the most common extracranial solid tumor in childhood accounting for 8–
10% of all childhood malignancies. The tumor is characterized by a spectrum of …

PURPOSE In neuroblastoma (NB), the ALK receptor tyrosine kinase can be constitutively
activated through activating point mutations or genomic amplification. We studied ALK …

Neuroblastoma has heterogenous clinical presentations that are reflected by several well-
defined clinical factors and biomarkers. Combinations of these clinical and biologic …

For children with neuroblastoma, the likelihood of cure varies widely according to age at
diagnosis, disease stage, and tumor biology. Treatments are tailored for children with this …